Abstract
Many new drugs in the future will be very expensive and have major resource implications. Given current structures and legislation covering the prescribing of drugs, there are no clear means of controlling the use of these drugs to avoid diverting money away from other health care services and into drug treatment. This paper considers what mechanisms might be used by a purchaser to manage the introduction of an expensive new drug and uses interferon beta-1b for treating multiple sclerosis as an example. The most likely mechanism is the prescribing of the drug by a general practitioner on the advice of a neurologist. This would achieve a good benefit for the resources invested but would not control total expenditure. Devolving a limited budget for the drug to a specialist centre so that neurologists may prescribe it directly would be preferable, as this would link clinical, prescribing, and budgetary responsibility. These issues need to be addressed urgently by purchasers if major disruptions of services are to be avoided.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bochner F., Martin E. D., Burgess N. G., Somogyi A. A., Misan G. M. How can hospitals ration drugs? Drug rationing in a teaching hospital: a method to assign priorities. Drug Committee of the Royal Adelaide Hospital. BMJ. 1994 Apr 2;308(6933):901–905. doi: 10.1136/bmj.308.6933.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Crump B. J., Panton R., Drummond M. F., Marchment M., Hawkes R. A. Transferring the costs of expensive treatments from secondary to primary care. BMJ. 1995 Feb 25;310(6978):509–512. doi: 10.1136/bmj.310.6978.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goodkin D. E. Interferon beta-1b. Lancet. 1994 Dec 17;344(8938):1702–1703. doi: 10.1016/s0140-6736(94)90484-7. [DOI] [PubMed] [Google Scholar]
- Gould J. Medicine's core values. Profession should not have to make decisions concerning rationing. BMJ. 1994 Dec 17;309(6969):1657–1657. doi: 10.1136/bmj.309.6969.1657b. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R., Rawlins M. D. Prescribing at the interface between hospitals and general practitioners. BMJ. 1992 Jan 4;304(6818):4–5. doi: 10.1136/bmj.304.6818.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leufkens H., Haaijer-Ruskamp F., Bakker A., Dukes G. Scenario analysis of the future of medicines. BMJ. 1994 Oct 29;309(6962):1137–1140. doi: 10.1136/bmj.309.6962.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nishimura L. Y., Shane R. Therapeutic dilemmas. An approach to the management of expensive pharmaceutical advances. Pharmacoeconomics. 1994 Dec;6(6):498–505. doi: 10.2165/00019053-199406060-00003. [DOI] [PubMed] [Google Scholar]
- Orme M. How to pay for expensive drugs. BMJ. 1991 Sep 14;303(6803):593–594. doi: 10.1136/bmj.303.6803.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paty D. W., Li D. K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):662–667. doi: 10.1212/wnl.43.4.662. [DOI] [PubMed] [Google Scholar]
- Walley T., Edwards R. T. Is there a need for an independent centre for pharmacoeconomics in the UK? Pharmacoeconomics. 1994 Feb;5(2):93–100. doi: 10.2165/00019053-199405020-00003. [DOI] [PubMed] [Google Scholar]